Lucas Brent T. 4

4 · Envoy Medical, Inc. · Filed Feb 17, 2026

Research Summary

AI-generated summary of this filing

Updated Feb 17, 2026

Envoy Medical (COCH) CEO Lucas Brent Buys 62,500 Shares

What Happened
Lucas Brent, CEO of Envoy Medical, acquired 62,500 shares on 2026-02-12 at $0.40 each for a cash outlay of $25,000 (transaction code P). The Form 4 also reports two derivative acquisitions (reported at $0.00) of 37,500 and 62,500 shares on the same date (totaling 100,000 shares), which appear to be issuances tied to previously granted options/warrants (see footnotes).

Key Details

Transaction date: February 12, 2026; Form 4 filed February 17, 2026. Filing appears timely under the SEC two-business-day rule (Feb 16 was a federal holiday).
Cash purchase: 62,500 shares @ $0.40 = $25,000.
Derivative acquisitions: 37,500 shares @ $0.00 and 62,500 shares @ $0.00 (total 100,000 shares reported as derivative issuances).
Shares owned after transaction: not specified in the materials provided.
Relevant footnotes:
- F1: Options to purchase 659,811 shares vested 10/15/2023; 219,938 shares vest pro rata monthly over 36 months.
- F2: Options to purchase 50,000 shares vest 2/5/2027; 150,000 vest pro rata monthly over 36 months.
- F3: Fully exercisable.
- F4: Exercisable upon shareholder approval to issue Class A common shares underlying warrants.
- F5/F6: Series A-1/A-2 warrant expirations are tied to FDA milestones for the Acclaim CI Device (shorter windows once milestones hit).

Context

The $25,000 cash purchase is a direct buy and is more informative to investors than routine sales; the derivative entries at $0 likely reflect issuance on option vesting/exercise or warrant conversion per the footnotes (the filing does not detail cashless vs. cash exercises).
Footnotes show multiple vesting schedules and FDA-tied warrant terms; these affect when additional shares may be issued or exercised.
No sales were reported in this filing.

Insider Transaction Report

Form 4

Period: 2026-02-12

Envoy Medical, Inc.COCH

Lucas Brent T.

DirectorChief Executive Officer

Transactions

Purchase
Class A Common Stock
2026-02-12$0.40/sh+62,500$25,000→ 297,090 total
Purchase
Warrant (right to buy)
[F4][F5]
2026-02-12+37,500→ 37,500 total
Exercise: $0.40→ Class A Common Stock (37,500 underlying)
Purchase
Warrant (right to buy)
[F4][F6]
2026-02-12+62,500→ 62,500 total
Exercise: $0.40→ Class A Common Stock (62,500 underlying)

Holdings

Stock Option (right to buy)
[F1]
Exercise: $2.40Exp: 2033-10-15→ Class A Common Stock (879,749 underlying)
879,749
Stock Option (right to buy)
[F2]
Exercise: $0.53Exp: 2036-02-05→ Class A Common Stock (200,000 underlying)
200,000
Warrant (right to buy)
[F3]
Exercise: $11.50Exp: 2028-09-29→ Class A Common Stock (110,987 underlying)
110,987

Footnotes (6)

[F1]Options to purchase 659,811 shares vest on 10/15/2023, and 219,938 shares vest pro rata on the 15th of each month thereafter for 36 consecutive months.
[F2]Options to purchase 50,000 shares vest on 2/5/2027, and 150,000 shares vest pro rata on the 5th of each month thereafter for 36 consecutive months.
[F3]Fully exercisable.
[F4]Exercisable upon shareholder approval of the issuance of shares of Class A Common Stock underlying the warrants.
[F5]The Series A-1 Warrants expire on the earlier of (i) two years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has submitted a Premarket Approval Application to the Food and Drug Administration (FDA) for its Acclaim CI Device.
[F6]The Series A-2 Warrants expire on the earlier of (i) five years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has received FDA approval for its Acclaim CI Device.

Signature

s/ Andrew Nick as Attorney-in-Fact for Brent Lucas pursuant to Power of Attorney previously filed.|2026-02-16

Documents

1 file

4
form4.xmlPrimary
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES